Fabio S. Conforti
Bergamo, 24125, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 117 publications
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients.
Journal: JAMA network open
Published: May 04, 2026
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 15, 2026
"Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?"
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 15, 2026
From intravenous to subcutaneous pertuzumab/trastuzumab in breast cancer: Clinical and pharmacoeconomic drivers and barriers to switching.
Journal: Tumori
Published: December 15, 2025
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME database.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 27, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 17, 2025
Response to Sahin, Guven, and Aksoy.
Journal: Journal of the National Cancer Institute
Published: August 22, 2025
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.
Journal: Current oncology (Toronto, Ont.)
Published: August 17, 2025
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer".
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2025
Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma.
Journal: Cancer
Published: June 29, 2025
Lung Carcinoids in Adolescents and Young Adults (AYAs): A Still Overlooked Clinical Entity.
Journal: Current oncology (Toronto, Ont.)
Published: June 26, 2025
Last Updated: 09/26/2026